How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,452 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Alcohol Biosensor Monitoring for Alcoholic Liver Disease

: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Information provided by (Responsible Party): Andrea DiMartini, University of Pittsburgh Study Details Study Description Go to Brief Summary: Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol use (...) Inclusion Criteria: Patients with AALD followed at our liver disease clinic, 18 years or older, willing to accept randomization, and agree to wear device for 3 months, SOCRATES problem recognition subscale score >26 (scores <26 indicate very low recognition of an alcohol problem). Exclusion Criteria: Non-English speaking, Montreal Cognitive Assessment (MOCA) scores <21 (moderate cognitive impairment) or neurologic diseases (e.g. Parkinson's), patients with unresponsive acute alcoholic hepatitis, multi

2018 Clinical Trials

142. The management of non-alcoholic fatty liver disease

and of a daily alcohol consumption P30g for men and P20g for women [1]. Alcohol consumption above these limits indicates alcoholic liver disease. The relationship between alcohol and liver injury depends on several cofactors (type of alcoholic beverage, drinking patterns, duration of exposure, individual/genetic susceptibility), rendering simple quantitative thresholds at least partly arbitrary. Speci?cally, patients consuming moderate amounts of alcohol may be still predisposed to NAFLD if they have (...) with IR and/or metabolic risk factors (i.e. obesity or metabolic syndrome [MetS]) should undergo diagnostic procedures for the diagnosis of NAFLD, which relies onthe demonstration of excessive liver fat (A1) ? Individuals with steatosis should be screened for secondary causes of NAFLD, including a careful assessment of alcohol intake. The interaction between moderate amounts of alcohol and metabolic factors in fatty liver should always be considered (A1) ? Other chronic liver diseases that may coexist

2016 European Association for the Study of the Liver

143. Alcohol: Adult Unhealthy Drinking

alcohol for cardiovascular benefits. Pregnancy Alcohol is a known teratogen. Any alcohol that a pregnant woman drinks passes quickly through the placenta to the fetus, which can result in physical, psychological, behavioral, and cognitive problems for the child. There is no safe amount of alcohol in pregnancy. The risk of fetal alcohol syndrome increases with increasing alcohol consumption (ACOG 2013). Lactation Alcohol consumption by lactating women results in reduced milk consumption, decreased (...) the terms “alcohol abuse” and “alcohol dependence,” but research showed that symptoms of abuse and dependence were all symptoms of a single disorder. Unhealthy drinking is drinking alcohol at levels that are associated with adverse health effects and/or alcohol use disorder. The following behaviors are considered unhealthy drinking, although they are not AUDs according to DSM-5: Risky drinking is exceeding recommended drinking limits (see below). It not only increases the risk of alcohol use disorder

2016 Kaiser Permanente Clinical Guidelines

144. Vitamin B6 metabolism in chronic alcohol abuse The effect of ethanol oxidation on hepatic pyridoxal 5'-phosphate metabolism. Full Text available with Trip Pro

Vitamin B6 metabolism in chronic alcohol abuse The effect of ethanol oxidation on hepatic pyridoxal 5'-phosphate metabolism. Individuals with chronic alcohol abuse frequently exhibit lowered plasma levels of pyridoxal 5'-phosphate, the coenzyme form of vitamin B6. Because the liver is the primary source of this coenzyme in plasma and also the principal organ that oxidizes ethanol, the effect of ethanol on hepatic pyridoxal phosphate metabolism was studied in the rat. The chronic feeding (...) of ethanol (36 percent of the total dietary calories) for 6 wk significantly decreased the hepatic pyridoxal phosphate content both in animals given a sufficient amount of vitamin B6 in their diet and in those rendered vitamin B6 deficient. In isolated perfused livers, the addition of 18 mM ethanol lowered the pyridoxal phosphate content of livers from vitamin B6-sufficient animals and deceased the net synthesis of pyridoxal phosphate from pyridoxine by the livers of vitamin B6-deficient animals. Ethanol

1975 Journal of Clinical Investigation

145. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (Abstract)

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury, and progressive liver fibrosis. Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. We aimed (...) to assess the safety and efficacy of resmetirom in patients with NASH.MGL-3196-05 was a 36-week randomised, double-blind, placebo-controlled study at 25 centres in the USA. Adults with biopsy confirmed NASH (fibrosis stages 1-3) and hepatic fat fraction of at least 10% at baseline when assessed by MRI-proton density fat fraction (MRI-PDFF) were eligible. Patients were randomly assigned 2:1 by a computer-based system to receive resmetirom 80 mg or matching placebo, orally once a day. Serial hepatic fat

2019 Lancet

146. Gut Hormones in Obesity, Nicotine and Alcohol Dependence

. For individual groups: i) Overweight/obese group: history of or current alcohol abuse or dependence; nicotine use other than "never smoked", i.e. >100 cigarettes lifetime use; history of dependence, abuse or heavy recreational use of cocaine, cannabis, opiates or other substance of abuse; history of problem gambling. Any previous or current psychiatric diagnosis listed in DSM-V Axis I, which in the opinion of the clinical team will compromise conduct and interpretability of the study. ii) Abstinent tobacco (...) dependent group: history of or current alcohol abuse or dependence; current dependence for cocaine, cannabis, opiates or other substance of abuse, or problem gambling (previous history will be allowed); taking varenicline, bupropion or other prescription medications for smoking cessation. Any previous or current psychiatric diagnosis listed in DSM-V Axis I, which in the opinion of the clinical team will compromise conduct and interpretability of the study. iii) Abstinent alcohol dependent group: current

2015 Clinical Trials

147. Cerebral Hemodynamics With rTMS in Alcohol Dependence

of Psychiatry, Ranchi, India Study Details Study Description Go to Brief Summary: The present study measures the cerebral hemodynamic indices of alcohol dependent patients and observe the relative changes in these parameters with rTMS application. Condition or disease Intervention/treatment Phase Alcohol Dependence Device: Repetitive Transcranial Magnetic Stimulation (rTMS) Not Applicable Detailed Description: Alcohol abuse is a worldwide problem causing serious physical, psychological, social and economic (...) dependence, [1] as well as in acute stage of intoxication, but an increase after resolution of withdrawal state. [12] However, ethanol in low concentration has been found to increase the systolic, diastolic and mean blood flow velocity in middle cerebral arteries (MCA), anterior cerebral arteries (ACA) and decrease the resistance indices by reducing the cerebrovascular resistance in healthy individuals. Studies have reported that alcohol related hepatic dysfunction results in increased blood viscosity

2015 Clinical Trials

148. Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence

of psychotropic medications is allowed, but any use must be discontinued prior to the study for a time period exceeding 5 half-lives of the medication in question. Presence of any current or past DSM IV diagnosis of bipolar disorder, or psychotic disorder (e.g, schizophrenia, schizoaffective disorder), or current substance dependence other than alcohol, nicotine, or caffeine. Major medical problems (e.g., central nervous system (CNS), cardiovascular, respiratory, gastrointestinal (GI), hepatic, renal (...) dependence other than nicotine, or caffeine. Major medical problems (e.g., CNS, cardiovascular, respiratory, GI, hepatic, renal, endocrine, HIV, reproductive) that in the judgment of the PI, in consultation with relevant Clinical Center consult services, cannot be adequately managed at the Clinical Center Presence of ferromagnetic objects in the body, fear of enclosed spaces, or other standard contraindication to MRI, as determined by self-report Current or past DSM IV diagnosis of alcohol dependence

2015 Clinical Trials

149. Reducing Alcohol Dependence Among HIV-Positive Individuals

on the Clinician's Guide, a brief intervention for heavy drinking in primary care settings advocated by the National Institute on Alcohol Abuse and Alcoholism, or Motivational Interviewing. Participants will be assessed at baseline, 30, 60, 90 days, 6 and 12 months after baseline. By the end of treatment (60 days) and throughout the follow-up period, alcohol use is expected to highest among participants who receive the Clinician's Guide alone, intermediate among participants who receive the enhanced Clinician's (...) Guide, and lowest among participants who receive enhanced Motivational Interviewing. Condition or disease Intervention/treatment Phase Alcohol Dependence Behavioral: Clinician's Guide Behavioral: Enhanced Motivational Interviewing Behavioral: Enhanced Clinician's Guide Not Applicable Detailed Description: HIV infection is a widespread health problem in the U.S. Antiretroviral (ART) therapy has increased longevity and changed the nature of risk factors for morbidity and mortality. Alcohol consumption

2015 Clinical Trials

150. Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age Full Text available with Trip Pro

Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age There is a gap between the association of non-alcoholic fatty liver disease (NAFLD) and renal function in an apparently healthy population. This study aims to assess whether NAFLD is associated with estimated glomerular filtration rate (eGFR) levels and to understand early changes of eGFR in NAFLD. A cross-sectional study was performed among apparently healthy persons who underwent (...) general health screening including laboratory assessments and hepatic ultrasonography from January 2013 to December 2013 at the First Affiliated Hospital of Zhejiang University, College of Medicine, China. This study included 1,193 subjects with a mean age of 48 years. Prevalence of NAFLD was 31.3%. Mean eGFR was significantly lower in NAFLD than in controls (107 ± 19 mL/min/1.73 m(2) vs. 113 ± 23 mL/min/1.73 m(2), P<0.001). Correlation analysis between eGFR and NAFLD related risk factors revealed

2015 PloS one

151. Effectiveness of Zonisamide in Alcohol Dependent Veterans

drinking and overall drinking in 160 treatment-seeking, regularly heavy drinking, alcohol-dependent Veterans who want to quit drinking or reduce consumption to non-hazardous levels. The investigators will use state-of-the-art methodology and outcome assessments, including medical management (MM) therapy (a minimal behavioral intervention aimed at reinforcing treatment goals and adherence to medication), which is simple and easily implemented in primary care settings. The use of MM in the study (...) Score (AUQ) [ Time Frame: over 16 weeks (weeks 1-16) ] This is the change in AUQ scores (urge to drink) measured weekly compared between groups using repeated measures Change in quality of life [ Time Frame: over 16 weeks (weeks 1-16) ] Change in quality of life scores measured by the Q-LES-Q Changes in level of alcohol-related problems [ Time Frame: over 16 weeks (weeks 1-16) ] Change in level of alcohol-related problems measured by the Short Index of Problems (SIP) Eligibility Criteria Go

2015 Clinical Trials

152. A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02382276 Recruitment Status : Completed First Posted : March 6, 2015 Last

2015 Clinical Trials

153. Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia Full Text available with Trip Pro

Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia 25628574 2015 01 28 2018 11 13 1664-0640 5 2014 Frontiers in psychiatry Front Psychiatry Accessibility and affordability of alcohol dependency medical care in serbia. 192 10.3389/fpsyt.2014.00192 Jakovljevic Mihajlo B MB Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia. Jovanovic Mirjana M Department of Psychiatry, Faculty of Medical Sciences (...) , University of Kragujevac , Kragujevac , Serbia. Lesch Otto Michael OM Department of Psychiatry and Psychotherapy, Medical University of Vienna , Vienna , Austria. eng Journal Article Review 2015 01 12 Switzerland Front Psychiatry 101545006 1664-0640 Serbia access addiction affordability alcohol dependency economics medical care 2014 10 28 2014 12 16 2015 1 29 6 0 2015 1 30 6 0 2015 1 30 6 1 epublish 25628574 10.3389/fpsyt.2014.00192 PMC4290475 Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):207-13 23745345 Acta

2015 Frontiers in Psychiatry

154. The effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. Full Text available with Trip Pro

The effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. Non-alcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease with few therapeutic options. Resveratrol (RSV) prevents the development of steatosis in a number of experimental fatty liver (non-alcoholic fatty liver [NAFL]) models, but the preventive or therapeutic effects on experimental NASH are not yet clarified, and clinical results on non (...) -alcoholic fatty liver disease are ambiguous. Thus, we aimed to compare the RSV-mediated preventive and therapeutic effects on experimental NAFL and NASH.We used a high-fat (HF) diet to generate a rat NAFL model and a high-fat, high-cholesterol (HFC) diet to generate a rat NASH model. The preventive and therapeutic potential of RSV was tested by adding RSV to the HF and HFC diet from study start or after 1 week of the diets. Animals were sacrificed after 8 weeks with appropriate controls. Blood and liver

2015 Journal of gastroenterology and hepatology

155. Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles. Full Text available with Trip Pro

Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles. The mechanisms by which hepatocyte exposure to alcohol activates inflammatory cells such as macrophages in alcoholic liver disease (ALD) are unclear. The role of released nano-sized membrane vesicles, termed extracellular vesicles (EV), in cell-to-cell communication has become increasingly recognized. We tested the hypothesis that hepatocytes exposed (...) experiments demonstrated a critical role of CD40 ligand (CD40L) in EV mediated macrophage activation. In vivo, wild-type mice receiving a pan-caspase, Rho kinase inhibitor or with genetic deletion of CD40 (CD40(-/-)) or the caspase-activating TRAIL receptor (TR(-/-)), were protected from alcohol-induced injury and associated macrophage infiltration. Moreover, serum from patients with alcoholic hepatitis showed increased levels of CD40L enriched EV.In conclusion, hepatocytes release CD40L containing EV

2015 Journal of Hepatology

156. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. (Abstract)

Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. Alcoholic hepatitis is characterised by florid hepatic inflammation, liver failure, and death within 28 days in 35% of patients. We recently showed proliferative peripheral blood mononuclear cell (PBMC) responses to alcohol dehydrogenase (ADH) in patients with alcohol-related cirrhosis, associated with T-helper-type 1 (Th1) immunity and disease severity. We aimed to define whether ADH-specific cellular (...) immunity is present in alcoholic hepatitis.PBMCs were collected from 15 patients with alcoholic hepatitis (modified Maddrey's discriminant function >32), nine with alcohol-related cirrhosis (long-term alcohol abstinence), and three healthy controls. 25 overlapping peptides, spanning the human ADH β1 subunit, were constructed. Proliferation to ADH peptides (1 × 10(5) cells per well, cultured with 10 mM peptides for 7 days) was assessed by (3)H-thymidine incorporation. A stimulation index (SI) of 2·5

2015 Lancet

157. Cohort study: In patients with a first episode of severe alcoholic hepatitis non-responsive to medical therapy, early liver transplant increases 6-month survival

Cohort study: In patients with a first episode of severe alcoholic hepatitis non-responsive to medical therapy, early liver transplant increases 6-month survival In patients with a first episode of severe alcoholic hepatitis non-responsive to medical therapy, early liver transplant increases 6-month survival | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In patients with a first episode of severe alcoholic hepatitis non-responsive

2013 Evidence-Based Medicine

158. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Full Text available with Trip Pro

Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Problem alcohol use is common among illicit drug users and is associated with adverse health outcomes. It is also an important factor in poor prognosis among drug users with hepatitis C virus (HCV) as it impacts on progression to hepatic cirrhosis or opiate overdose in opioid users.To assess the effects of psychosocial interventions for problem alcohol use in illicit drug users (...) (principally problem drug users of opiates and stimulants).We searched the Cochrane Drugs and Alcohol Group trials register (November 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 11, November 2011), PUBMED (1966 to 2011); EMBASE (1974 to 2011); CINAHL (1982 to 2011); PsycINFO (1872 to 2011) and reference list of articles. We also searched: 1) conference proceedings (online archives only) of the Society for the Study of Addiction (SSA), International Harm

2012 Cochrane

159. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Full Text available with Trip Pro

to compare clinical effectiveness and cost-effectiveness of integrated alcohol treatment compared to enhanced treatment as usual (TAU) on alcohol consumption and economic outcomes among patients ever infected with HCV.Patients recruited from three liver centers who had current or prior chronic HCV and qualifying alcohol screener scores were randomly assigned to enhanced TAU or the Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention. All patients received enhanced TAU, consisting of a patient (...) The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommended but only performed in patients with severe alcohol use disorders.This pragmatic randomized controlled trial seeks

2018 Contemporary clinical trials Controlled trial quality: uncertain

160. Time course of compromised urea synthesis in patients with alcoholic hepatitis. (Abstract)

Time course of compromised urea synthesis in patients with alcoholic hepatitis. Alcoholic hepatitis (AH) markedly decreases the urea synthesis capacity. We aimed to investigate the time course of this compromised essential liver function in patients with AH and its relation to treatment and survival.Thirty patients with AH were included in a prospective cohort study. We measured the substrate-independent urea synthesis capacity, i.e., the functional hepatic nitrogen clearance (FHNC (...) ), in the patients at study entry and again at three months (survivors/available: n = 17). Patients with severe disease (Glasgow Alcoholic Hepatitis Score ≥9, n = 17) were randomized to receive either prednisolone or pentoxifylline and were in addition examined after 14 days (n = 9).FHNC (normal range = 25-45 L/h) was markedly decreased at study entry (median = 5.6 (IQR = 3.0-9.6) L/h) and increased by three-fold in survivors at three months (15.1 (12.0-22.9) L/h; p < .001). In patients with severe AH, FHNC

2018 Scandinavian journal of gastroenterology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>